Jaguar Health Inc.

NASDAQ: JAGXHealthcare / Biotechnology / USA
1.3300.00Vol 1 167 1581Y Perf -96.51%
Sep 13th, 2019 16:00
BID1.33 ASK1.34
Open1.34 Previous Close1.33
Pre-Market1.31 After-Trading1.33
 -0.02 -1.50%  - -%
Target Price
10.00 
Analyst Rating
Moderate Buy 2.00
Potencial %
651.88 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/100 
Growth Ranking
★+ —    -
Insiders Shares Cnt. % 3/6/12M
100/100/100 
Income Ranking
 —    -
Market Cap (mil)62 
Earnings Rating
Strong Buy
Price Range Ratio 52wk %
0.19 
Earnings Date
26th Aug 2019

Today's Price Range

1.261.40

52wk Range

1.00175.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
17.70%
1 Month
-12.50%
3 Months
-78.55%
6 Months
731.25%
1 Year
-96.51%
3 Years
-92.15%
5 Years
-
10 Years
-

Name / TickerPriceChg.Chg.%
JAGX1.330.00000.00
AAPL218.75-4.3300-1.94
GOOG1 239.565.31000.43
MSFT137.32-0.2000-0.15
XOM72.640.66000.92
WFC48.920.27000.55
JNJ130.780.35000.27
FB187.19-0.2800-0.15
GE9.340.09000.97
JPM120.232.32001.97
Earnings HistoryEstimateReportedSurprise %
Q02 2019-5.61-9.09-62.03
Q01 2019-13.29-12.595.27
Q03 2017-0.13-
Q02 2017-0.22-0.1245.45
Q01 2017--0.28-
Q03 2016-0.40-0.3025.00
Q02 2016-0.42-0.3516.67
Q01 2016-0.49-0.4312.24
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.8886.16Positive
12/2019 QR-0.4092.93Positive
12/2019 FY-6.1182.36Positive
12/2020 FY-0.9883.83Positive
Next Report Date-
Estimated EPS Next Report-5.61
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1 167 158
Shares Outstanding (in ths.)46 363
Trades Count1 608
Dollar Volume978 792
Avg. Volume440 190
Avg. Weekly Volume2 216 361
Avg. Monthly Volume1 828 050
Avg. Quarterly Volume912 528
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

Jaguar Health Inc.

Jaguar Health Inc is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products. The company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the marketplace from plants used traditionally in rainforest areas. It operates into two business segments namely Humal health and animal health. Its Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

CEO: Lisa A Conte

Teplephone: +1 415 371-8300

Address: 201 Mission Street, San Francisco 94105, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

33%67%

Bearish Bullish

64%36%

Bearish Bullish

51%49%

News